|Bid||68.84 x 1100|
|Ask||69.04 x 1100|
|Day's Range||68.60 - 70.58|
|52 Week Range||61.01 - 82.27|
|Beta (3Y Monthly)||1.35|
|PE Ratio (TTM)||19.95|
|Forward Dividend & Yield||0.66 (0.94%)|
|1y Target Est||N/A|
Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire privately-owned BioTek Instruments for $1.165 billion. With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately $1.05 billion. BioTek is a global leader in the design, manufacture and distribution of innovative life science instrumentation.
Agilent Technologies Inc. (NYSE:A) today introduced its first new product from recently acquired ACEA Biosciences, at the 34th Congress of the International Society for Advancement of Cytometry, CYTO 2019 Congress, being held June 22–26, 2019 in Vancouver, Canada. The Agilent NovoCyte Advanteon Flow Cytometer is now one of the most sensitive cell analyzers available on the market. Flow cytometers are integral to basic research, drug discovery, and clinical diagnostics.
Agilent Technologies Inc. (NYSE:A) today announced the opening of a production facility in Colorado that more than doubles its capacity to develop and manufacture “oligos,” which are short DNA and RNA molecules that customers use to produce nucleic acid-based therapeutics. Agilent expects the demand for therapeutic oligo manufacturing to grow near 10% each year through 2025, to over $750 million by 2025. This facility will enable Agilent to meet this growing demand and to continue being a partner of choice to pharmaceutical and biotech companies.
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA®
Agilent Technologies Inc. (NYSE:A) announced today the results of its first Pharma Lab Leaders Survey looking to gather insights from pharmaceutical, biopharmaceutical, and contract research laboratories in seven countries around the world. Respondents included 650 laboratory managers, directors, and supervisors from China, Germany, India, South Korea, Switzerland, Austria, and the United States. “We were extremely pleased that Agilent wanted to work with us again to explore the challenges and opportunities within this unique group of laboratories,” said Paljit Sohal, principal consultant, of Frost & Sullivan.
Agilent Technologies Inc. (NYSE:A) introduced the newest member of its LC/MS portfolio today at the American Society for Mass Spectrometry Conference (ASMS) which is being held June 2 through June 6 in Atlanta, Georgia. The new Agilent InfinityLab LC/MSD iQ System incorporates ‘designed-in’ smart features, software, and hardware developed specifically for chemists and chromatographers who will benefit from the intuitive design and greater level of detail generated by a mass selective detector. An early maintenance feedback feature allows lab managers to plan routine maintenance on the lab’s schedule resulting in a focus on overall productivity.
Agilent Technologies, Inc. (NYSE:A) today announced that a quarterly dividend of 16.4 cents per share of common stock will be paid on July 24, 2019, to all shareholders of record as of the close of business on July 2, 2019. Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
Agilent Technologies Inc. (NYSE:A) announces a unified portfolio of products for immunotherapy researchers. The innovative solution will showcase at Immunology 2019, the 103rd Annual Meeting of the American Association of Immunologists (AAI), taking place in San Diego, CA on May 9-13, 2019. “Immunotherapy is changing the landscape of cancer treatment, but most of the available tools are adapted and not purpose-built for this cell-centric workflow,” said David Ferrick, Ph.D., senior director of the Cell Analysis Division at Agilent Technologies.
Agilent Technologies, Inc. (NYSE:A) and SomaLogic, Inc. (a privately held biotechnology company) today announced a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic’s novel SOMAscan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development. SomaLogic’s SOMAscan assay solves a protein measurement challenge using a DNA measurement solution, enabling the accurate measurement of an individual’s protein makeup with unequalled sensitivity and dynamic range.
PD-L1 IHC 22C3 pharmDx Can Now Be Used to Identify a Broader Range of NSCLC Patients for First-line Treatment With KEYTRUDA®
The new xCELLigence RTCA ePacer provides a solution that uses electrical pacing to functionally mature cardiomyocytes. On March 11, 2019, ACEA Biosciences – A Part of Agilent unveiled the new xCELLigence® RTCA ePacerTM during their workshop held at the Society of Toxicology (SOT) Annual Meeting in Baltimore. Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) are increasingly being used as a human-relevant in vitro model system for drug discovery, safety pharmacology, and cardiac disease research.
Agilent Technologies Inc. will release second-quarter fiscal 2019 financial results after the stock market closes on May 14. The company will host a live webcast of its investor conference call in listen-only mode.
Increased capabilities for food testing, environmental screening, and metabolomics research with new systems and software workflows
Agilent Technologies Inc. (NYSE:A) today announced that Professor Antoni Ribas has received an Agilent Thought Leader Award in support of his genomics and immunotherapy research. A renowned oncologist, Dr. Ribas is implementing next-generation genomics solutions to identify mechanisms and biomarkers associated with resistance and response to immunotherapy in patients with melanoma. Dr. Ribas is a professor of medicine and surgery as well as molecular and medical pharmacology at the University of California at Los Angeles (UCLA).
Agilent Technologies Inc. (NYSE:A) announced today the shipping of a new instrument that offers laboratories a more affordable, low-throughput option for analyzing the quality of RNA and DNA samples. “The Agilent 4150 TapeStation system makes quality control in next-generation sequencing easier, faster, and more economical than ever,” said Knut Wintergerst, general manager of Agilent’s Biomolecular Systems and Solutions product line. “Laboratories that have limited budgets will now be able to take advantage of all the features and benefits of our ScreenTape technology: ease of use, constant cost per sample, fast and accurate results, and minimal hands-on time,” Wintergerst explained.
Agilent Technologies Inc. (NYSE:A) today announced that it will host the western regional conference of the National Academy of Engineering, along with a technical symposium—Bioengineering, Advancing Our World—at company headquarters in Santa Clara, California, on March 28, 2019. Open to the public, the symposium will be led by Darlene Solomon, Agilent senior vice president, and chief technology officer.
Agilent Technologies Inc. (NYSE:A) today announced that surveys conducted by the Great Place to Work Institute indicate that Agilent ranks among the best places to work in both Spain and Germany. Great Place to Work is a recognition program that conducts the largest workplace culture study in the world, with 6,000 companies participating. The institute’s latest survey results found that around 90 percent of Agilent employees said that Agilent was a great workplace in both Spain and Germany, with around 85 percent stating that they take great pride in working for the company.
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Agilent Technologies Inc. (NYSE:A) today announced that it has received a Gartner Inc. Power of the Profession Award in the category of Talent Payback of the Year, a prestigious honor that recognizes the company’s innovative manufacturing and supply-chain employee training program. The award was granted to Agilent’s OFS Academy, an online portal launched by the Order Fulfillment and Supply Chain organization in 2016 to inform and engage the global OFS team. The OFS Academy differentiates due to its reach and effectiveness.
Agilent Technologies Inc. (NYSE:A) and Imperial College London have announced that, as part of its ongoing collaboration, several state-of-the-art analytical instruments have been installed into the college’s Molecular Sciences Research Hub. The new Agilent Measurement Suite (AMS) will provide Imperial faculty, researchers, students, and collaborators access to the latest analytical instruments. With the help of Agilent instruments, scientists will be better able to push forward their interdisciplinary research in areas such as clinical diagnostics, biopharmaceuticals, energy and chemicals, materials, food, agriculture, and environmental testing.
Agilent Technologies, Inc. (NYSE:A) today announced a new next-generation sequencing (NGS) library preparation system designed to easily run complex DNA sequencing assays with the press of a button. “Since the inception of NGS, library preparation has been one of the most complex and variable parts of the NGS workflow,” stated Sam Raha, president of the company’s Diagnostics and Genomics Group. Providing a complete solution for NGS library preparation, the Magnis system is fully automated and delivers reproducible results with one-day turnaround time.